BRCA1 and ovarian cancer: Knockdown of REV1 expression using miR-96 contributed to cisplatin sensitization in bone osteosarcoma cells with intact HR repair, as well as in BRCA1-deficient breast cancer and BRCA2-deficient ovarian cancer cell lines with compromised HR pathways (223).